Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Notes Payables (2016 - 2020)

Historic Notes Payables for Altimmune (ALT) over the last 7 years, with Q2 2020 value amounting to $632000.0.

  • Altimmune's Notes Payables rose 28601.55% to $632000.0 in Q2 2020 from the same period last year, while for Jun 2020 it was $632000.0, marking a year-over-year increase of 28601.55%. This contributed to the annual value of $71596.0 for FY2018, which is 4405.05% up from last year.
  • Latest data reveals that Altimmune reported Notes Payables of $632000.0 as of Q2 2020, which was up 28601.55% from $105062.0 recorded in Q3 2019.
  • Altimmune's 5-year Notes Payables high stood at $1.5 million for Q3 2018, and its period low was $49702.0 during Q2 2017.
  • Over the past 5 years, Altimmune's median Notes Payables value was $134393.0 (recorded in 2019), while the average stood at $386259.6.
  • In the last 5 years, Altimmune's Notes Payables surged by 285211.46% in 2018 and then tumbled by 9283.96% in 2019.
  • Quarter analysis of 5 years shows Altimmune's Notes Payables stood at $458629.0 in 2016, then tumbled by 89.16% to $49702.0 in 2017, then skyrocketed by 44.05% to $71596.0 in 2018, then skyrocketed by 46.74% to $105062.0 in 2019, then soared by 501.55% to $632000.0 in 2020.
  • Its Notes Payables stands at $632000.0 for Q2 2020, versus $105062.0 for Q3 2019 and $163724.0 for Q2 2019.